Breaking News, Financial News

Financial Report: AbbVie

HUMIRA sales down 18% in the quarter due to biosimilar competition

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie 4Q Revenues: $8.3 billion (+7%) 4Q Loss: $1.8 billion (earnings were $52,000 4Q17) FY Revenues: $32.8 billion (+16%) FY Earnings: $5.7 billion (+7%) Comments: Global HUMIRA sales were $19.9 billion, up 8% for the year. In the U.S., HUMIRA sales grew 9% percent in the quarter. Internationally, HUMIRA sales declined 18% due to biosimilar competition. Global revenues from the hematologic oncology portfolio were $1.1 billion for the year, up 50%, with global IMBRUVICA sales of $1.0 bill...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters